Abstract:TOPIC: Pulmonary Vascular Disease TYPE: Original Investigations PURPOSE: The potential role of the gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) in pulmonary hypertension (PH) has never been elucidated. We aim to explore the association between TMAO and PH. METHODS: PH patients at Fuwai Hospital between October 2018 and February 2020 were enrolled. Patients received follow-up every three to six months through clinic visits. Plasma levels of TMAO were measured and associations with clinical markers including WHO-FC, NT-proBNP, hemodynamic parameters, and exercise capacity were explored. In monocrotaline (MCT)-induced PAH rat models, a normal diet and water supplemented with or without 1% 3,3-dimethyl-1-butanol (DMB), a kind of inhibitor of TMAO, were fed with for 4 weeks. Finally, rats received hemodynamic examinations, and after that blood serum as well as heart and lung tissues were collected. The ratio of right ventricle (RV) over left ventricle (LV) plus the septum was used as an index of RV hypertrophy (RVH). Elastic Van Gieson (EVG) stain was used to explore the changes of pulmonary vascular remodeling. RESULTS: One hundred and three consecutive PH patients were enrolled including patients with idiopathic/heritable pulmonary arterial hypertension (IPAH/HPAH, n=30), chronic thromboembolic PH (CTEPH, n=34), and congenital heart disease-associated PAH (CHD-PAH, n=39). After adjusting for confunders, TMAO levels were positively correlated with clinical disease severity assessed by WHO-FC, and also with NT-proBNP, hemodynamic parameters, and exercise capacity. TMAO responded to guideline-recommended treatment in patients with PH. It was noted that TMAO decreased significantly after treatment in patients with IPAH/HPAH. In linear correlation analysis, change in TMAO was positively associated with change in NT-proBNP (P=0.04) in IPAH/HPAH patients. Animal study showed that the level of TMAO in MCT-induced PH rats (22.2±8.7ng/mL) was higher than the MCT+DMB group (6.6±1.1ng/mL) and the control group (4.3±0.2ng/mL). Compared with MCT group, MCT+DMB group obtained a decreased RVH (30% vs 60%, p<0.001), right arterial pressure (4.4mmHg vs 6.2 mmHg, P=0.035), right ventricular systolic pressure (35.3mmHg vs 63.3mmHg, p<0.001), and mean pulmonary arterial pressure (22.5mmHg vs 39.5mmHg, p<0.001) as well as reduced vascular remodeling of lungs under pathological findings. CONCLUSIONS: TMAO was elevated in accordance with WHO-FC and decreased after guideline-recommended treatment in PH patients indicating higher TMAO might play an adverse effect on PH. The animal findings demonstrated that lower TMAO played a protective effect in MCT-induced PAH, which supported the clinical results. CLINICAL IMPLICATIONS: ①Demonstrated elevated TMAO was a risk factor for PH patients;②TMAO might be regarded as a novel indicator of PH patients. DISCLOSURES: No relevant relationships by Jianing Gao, source=Web Response no disclosure on file for Matthew C Konerman; no disclosure on file for Changming Xiong; No relevant relationships by Yicheng Yang, source=Web Response no disclosure on file for Qixian Zeng; no disclosure on file for Lemin Zheng

Gut Microbiota Dependent Trimethylamine N-oxide Aggravates Angiotensin II-induced Hypertension.

Gut Microbial Metabolite Trimethylamine N-Oxide Aggravates Pulmonary Hypertension.

Trimethylamine-N-Oxide Aggravates Kidney Injury via Activation of p38/MAPK Signaling and Upregulation of HuR

Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats

Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice

HIGHER CIRCULATING GUT MICROBIOTA-DEPENDENT METABOLITE TRIMETHYLAMINE N-OXIDE PLAYS AN ADVERSE EFFECT ON PULMONARY HYPERTENSION

Abstract P326: Trimethylamine, A Gut Bacteria Metabolite And Air Pollutant, Increases Blood Pressure, Proteinuria And Markers Of Kidney Damage In Rats.

Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats With Diabetic Kidney Disease

Inhibition of Microbiota-dependent Trimethylamine N-Oxide Production Ameliorates High Salt Diet-Induced Sympathetic Excitation and Hypertension in Rats by Attenuating Central Neuroinflammation and Oxidative Stress

Trimethylamine N-oxide promotes hyperoxaluria-induced calcium oxalate deposition and kidney injury by activating autophagy

TMAO is involved in kidney-yang deficiency syndrome diarrhea by mediating the "gut-kidney axis"

Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB

The Gut Microbial Metabolite Trimethylamine <i>N</i>-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis

Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways

High-circulating Gut Microbiota-Dependent Metabolite Trimethylamine N-oxide is Associated with Poor Prognosis in Pulmonary Arterial Hypertension.

The role of gut-dependent molecule trimethylamine N-oxide as a novel target for the treatment of chronic kidney disease

Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals

Gut Microbiota Metabolite TMA May Mediate the Effects of TMAO on Glucose and Lipid Metabolism in C57BL/6J Mice

TMAO Impairs Mouse Aortic Vasodilation by Inhibiting TRPV4 Channels in Endothelial Cells

Trimethylamine N-oxide promotes PERK-mediated endothelial-mesenchymal transition and apoptosis thereby aggravates atherosclerosis

Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: A Systematic Review and Meta-Analysis